Instalab

PTH Intact Test

The master switch behind your calcium, bone strength, and kidney mineral balance.

Who benefits from PTH Intact testing

Losing Bone Density Without a Clear Reason
This test reveals whether overactive parathyroid glands are quietly driving your bone loss.
Living with Kidney Disease
Your kidneys directly affect PTH levels, and tracking this number guides bone and mineral treatment decisions.
Told Your Calcium Is Borderline High
A calcium near the top of normal could mean a hidden parathyroid problem that only PTH testing can confirm.
Taking Vitamin D and Want Proof It's Working
This test shows whether your supplement is actually bringing your parathyroid system back into balance.

About PTH Intact

Your body keeps calcium in an extremely tight range because your heart, muscles, and nerves depend on it to function second by second. When calcium drifts even slightly, the parathyroid glands respond within minutes by adjusting how much PTH (parathyroid hormone) they release. A single PTH reading can reveal whether those glands are overactive, underactive, or being pushed into overdrive by something else entirely, like failing kidneys or a vitamin D shortage.

What makes this test especially useful is that PTH problems often hide behind normal-looking calcium on routine bloodwork. You can have a parathyroid gland quietly leaking too much hormone for years, slowly thinning your bones and seeding kidney stones, while your basic metabolic panel looks perfectly fine. Ordering intact PTH alongside calcium is the only reliable way to catch that pattern.

What PTH Does in Your Body

PTH is a small protein hormone produced by the parathyroid glands, four tiny structures behind your thyroid. When your blood calcium drops, a sensor on the parathyroid cells detects the change and triggers PTH release. PTH then acts on two main targets.

In the kidneys, PTH tells the filtering tubes to hold onto calcium instead of letting it pass into urine, while at the same time dumping phosphate. It also switches on the enzyme that converts stored vitamin D into its active form, which in turn boosts calcium absorption from your gut. In bone, PTH stimulates remodeling, the constant cycle of breaking down old bone and building new bone. At normal levels this keeps your skeleton healthy. At chronically high levels, the breakdown side wins, and bones weaken.

Heart Disease and Mortality Risk

PTH is not just a bone and calcium hormone. Receptors for PTH sit on heart muscle cells and blood vessel walls, and chronically elevated levels appear to carry cardiovascular consequences. In a study of about 3,200 patients who had dye-and-X-ray imaging of their heart arteries (the LURIC cohort), those in the highest quarter of intact PTH had roughly twice the risk of dying from cardiovascular causes and about 2.7 times the risk of sudden cardiac death compared to the lowest quarter, even after adjusting for kidney function, calcium, vitamin D, and traditional risk factors.

A study of about 2,300 older adults without prior heart disease (the CHS cohort) found that PTH above 65 pg/mL was linked to roughly 30% higher risk of heart failure over 14 years. When high PTH and low vitamin D occurred together, the risk of sudden cardiac death was about 2.2 times higher than when both were normal.

Not every study agrees. In about 10,400 community adults followed for 19 years (the ARIC study), higher PTH showed no independent positive link to coronary heart disease, stroke, or peripheral artery disease. If anything, the trend for cardiovascular death was weakly inverse. And in about 1,000 women from the Nurses' Health Study, PTH alone did not predict heart attacks or fatal coronary events after full adjustment.

The pattern that emerges is that PTH's cardiovascular signal is strongest in people who already have heart disease, kidney disease, or diabetes. In about 900 patients with coronary artery disease, those with type 2 diabetes and higher PTH had roughly double the mortality risk over six years, while PTH carried no independent risk in the non-diabetic group. If you are otherwise healthy, an elevated PTH is less likely to predict a heart event on its own, but it still warrants investigation because it usually points to an underlying mineral or hormonal problem.

Kidney Disease and Bone Health

Kidney disease is where PTH interpretation gets most complex. As kidney function declines, phosphate builds up, active vitamin D drops, and calcium falls. The parathyroid glands respond by pumping out more PTH, a condition called secondary hyperparathyroidism. By the time someone reaches dialysis, PTH levels can be many times the normal upper limit.

In dialysis populations, the relationship between PTH and death follows a U-shape: both very low and very high levels carry danger. In a European cohort of about 6,800 hemodialysis patients (COSMOS), the lowest mortality centered around a PTH of roughly 398 pg/mL, with a safer band spanning approximately 168 to 674 pg/mL. Patients below about 75 pg/mL had roughly 46% higher mortality, while those above 600 pg/mL had about double the mortality compared to the 150 to 300 pg/mL reference range in another large analysis of about 8,000 hemodialysis patients.

For bone health specifically, a Japanese study of over 180,000 hemodialysis patients found that each doubling of intact PTH was associated with a 6% higher odds of fracture, with a stronger effect for hip fractures. The same dataset showed that patients whose PTH dropped by more than 30% over one year had fewer fractures, suggesting the connection is not just statistical but reflects real bone biology.

The low end of the U-curve represents a condition called adynamic bone disease, where bone turnover is so suppressed that the skeleton cannot repair micro-damage. This leads to brittle bones and, paradoxically, increased calcium deposits in blood vessel walls. In one dialysis cohort, patients with a time-averaged intact PTH below 65 pg/mL had independently higher all-cause death and major cardiac events.

Primary Hyperparathyroidism

Primary hyperparathyroidism happens when one or more parathyroid glands develop a benign tumor (adenoma) and release PTH regardless of how high calcium climbs. It is the most common cause of high calcium in outpatients. The classic presentation includes kidney stones, bone loss, fatigue, and sometimes cognitive fog, but many people are diagnosed with only mildly elevated calcium on routine bloodwork.

Intact PTH catches roughly 93 to 99% of primary hyperparathyroidism cases, depending on the assay generation. The key diagnostic insight is that PTH should be suppressed when calcium is high. Any non-suppressed PTH in the setting of high blood calcium is abnormal, even if the PTH number falls within the lab's printed reference range. This subtlety is missed frequently: clinicians sometimes dismiss a "normal" PTH when calcium is elevated, delaying diagnosis for years.

Hypoparathyroidism

On the opposite end, too little PTH causes hypoparathyroidism. About 75% of cases result from accidental damage to the parathyroid glands during thyroid or neck surgery. The rest arise from genetic conditions, autoimmune destruction, or gland infiltration. Chronic PTH deficiency leads to low calcium, high phosphate, muscle cramps, tingling, and in severe cases seizures or heart rhythm problems.

After total thyroidectomy, a PTH drawn at 4 to 6 hours can predict who will develop significant low calcium. Values below about 10 pg/mL strongly predict trouble, with one study reporting near-perfect predictive accuracy (0.99 on a 0-to-1 scale) for temporary hypoparathyroidism and 0.96 for permanent disease. This early PTH check has become standard practice at many surgical centers because it allows same-day decisions about starting calcium and active vitamin D.

Reference Ranges

These ranges come from second-generation intact PTH assays used by most clinical laboratories and are based on vitamin D-replete adults with normal kidney function. Your lab may report slightly different numbers depending on the specific platform, and the reference range shifts meaningfully when the population used to set it includes vitamin D-deficient individuals (which inflates the upper limit by 25 to 35%).

CategoryRange (pg/mL)What It Suggests
Normal15 to 65Parathyroid glands are responding appropriately to calcium levels.
Mildly elevated66 to 150May reflect vitamin D deficiency, early kidney disease, or mild primary hyperparathyroidism. Needs context from calcium, vitamin D, and kidney function.
Moderately elevated150 to 300Common in moderate to advanced kidney disease. In the absence of kidney disease with high calcium, strongly suggests primary hyperparathyroidism.
Markedly elevatedAbove 300In kidney disease, associated with high bone turnover and fracture risk. Without kidney disease, suggests significant parathyroid pathology.
LowBelow 15Suggests hypoparathyroidism, most commonly after neck surgery. Should be evaluated with calcium and phosphate.

For people on dialysis, guidelines from KDIGO (Kidney Disease: Improving Global Outcomes) recommend keeping PTH between 2 and 9 times the upper limit of the specific assay's reference range, rather than a fixed number. This is because commercial intact PTH assays can differ by 40 to 50% on the same blood sample. The COSMOS dialysis study found the lowest mortality at approximately 398 pg/mL, with a safer corridor of roughly 168 to 674 pg/mL. Compare your results within the same lab over time for the most meaningful trend.

When Results Can Be Misleading

Intact PTH has a within-person biological variation (how much it naturally bounces around from day to day) of roughly 17 to 20%. In practical terms, a measured change of less than about 50 to 60% between two draws may just be noise. This is substantially higher than many other blood tests, so modest shifts should be interpreted cautiously.

  • Time of day: PTH follows a circadian rhythm, rising after about 8 PM, peaking between 2 and 4 AM, and returning to baseline by 8 AM. A late-afternoon draw will give a lower value than a predawn sample. Morning draws provide the most consistent results.
  • Season and vitamin D status: Winter draws tend to produce higher PTH because vitamin D levels drop with less sun exposure. A mildly elevated PTH in February might normalize by July without any intervention.
  • Kidney function: In chronic kidney disease, standard intact assays pick up biologically inactive PTH fragments that accumulate as filtration drops. In advanced CKD, these fragments can represent 30 to 50% of the measured value, inflating the result beyond what the parathyroid glands are actually secreting.
  • Recent neck surgery: After thyroidectomy or parathyroidectomy, PTH can drop sharply within hours, then rebound over the following 10 days to 3 months as bones remineralize. Testing during this window can mimic recurrent disease or false recovery.

Loop diuretics (such as furosemide) increase urinary calcium loss, which can stimulate PTH release over time. If you are taking a loop diuretic, your PTH may be higher than it would be otherwise, without any parathyroid gland abnormality. Proton pump inhibitors (PPIs) used long-term may reduce calcium and magnesium absorption, also nudging PTH upward. Neither drug causes true parathyroid disease, but both can produce readings that look suspicious.

Tracking Your Trend

A single PTH reading is a snapshot of a hormone that shifts throughout the day, responds to meals, seasons, and even posture. The real value comes from tracking your number over time using the same lab and assay. Given that commercial platforms can differ by 40 to 50% on the same sample, switching labs between draws makes comparison unreliable.

If your first result is abnormal, retest in 4 to 8 weeks with calcium, phosphate, vitamin D, and kidney function measured on the same draw. This rules out transient causes like a seasonal vitamin D dip or dehydration. If you are making changes (correcting vitamin D deficiency, adjusting calcium intake, or starting medication), recheck at 3 to 6 months to confirm the intervention is working, then at least annually once stable.

Because PTH naturally fluctuates by up to 50 to 60% between draws (the minimum change needed to be confident it is real), do not react to small fluctuations. A PTH of 72 pg/mL on one draw and 58 pg/mL three months later is likely biological noise. But a consistent upward drift from 45 to 70 to 95 pg/mL over a year, especially with rising calcium, is a meaningful trend that warrants investigation.

What to Do With an Abnormal Result

If your PTH comes back elevated, the first step is always to look at it alongside calcium, phosphate, vitamin D, and kidney function. These should ideally be drawn at the same time. The combination tells you which category you likely fall into.

  • High PTH with high calcium and normal kidneys: This pattern points to primary hyperparathyroidism. The next step is a referral to an endocrinologist, possibly with imaging to localize an adenoma and a bone density scan to assess skeletal impact.
  • High PTH with low or normal calcium and reduced kidney function: This is the expected pattern of secondary hyperparathyroidism in CKD. Work with a nephrologist to manage phosphate, vitamin D, and possibly drugs that make the parathyroid glands less active (calcimimetics).
  • High PTH with normal calcium and normal kidneys: Check 25-hydroxyvitamin D. If it is low (below about 30 ng/mL), vitamin D deficiency is the most likely driver. Correct it and recheck PTH in 3 to 6 months. If vitamin D is adequate and PTH stays elevated, consider normocalcemic primary hyperparathyroidism and pursue further evaluation.
  • Low PTH with low calcium: Suggests hypoparathyroidism. If this follows neck surgery, it may be temporary (check again at 6 to 12 months). If it persists beyond a year, it is likely permanent and requires calcium, active vitamin D, and possibly PTH replacement therapy under an endocrinologist.

The key principle is that PTH should never be interpreted in isolation. A number that looks alarming may be entirely expected given your kidney function, and a number that looks normal may be dangerously inappropriate if your calcium is elevated. Context is everything with this test.

What Moves This Biomarker

Evidence-backed interventions that affect your PTH Intact level

Decrease
Parathyroidectomy (surgical removal of overactive parathyroid tissue)
Removing the overactive gland is the gold standard for primary hyperparathyroidism, normalizing calcium in about 95% of patients at 6 months. In severe secondary hyperparathyroidism on dialysis, surgery achieved greater and more sustained PTH reduction than medication, and was associated with lower 6-year mortality (about 22% lower risk) compared to cinacalcet in a study of about 3,600 dialysis patients.
MedicationStrong Evidence
Decrease
Calcimimetics (cinacalcet, etelcalcetide, evocalcet, upacicalcet)
These drugs activate the calcium-sensing receptor on parathyroid cells, tricking the glands into thinking calcium is higher than it is, which shuts down PTH release. In randomized trials of hemodialysis patients, etelcalcetide (given intravenously three times per week) achieved a greater than 30% PTH reduction in about 74% of patients versus 8 to 10% on placebo over 26 weeks, and roughly half reached PTH at or below 300 pg/mL. Head-to-head, etelcalcetide outperformed oral cinacalcet (68% vs 58% achieving greater than 30% reduction; 52% vs 40% achieving greater than 50% reduction).
MedicationStrong Evidence
Decrease
Active vitamin D analogs (paricalcitol)
Paricalcitol activates the vitamin D receptor in parathyroid cells, directly slowing PTH production and gland growth. In a randomized trial of 78 hemodialysis patients, intravenous paricalcitol reduced mean intact PTH from about 795 to 406 pg/mL, roughly a 50% drop, over 12 weeks. About 68% of patients achieved at least a 30% reduction versus 8% on placebo.
MedicationStrong Evidence
Increase
PTH replacement therapy (recombinant PTH 1-84) for hypoparathyroidism
For people with hypoparathyroidism (too little PTH), daily injection of recombinant PTH 1-84 replaces the missing hormone. In a randomized trial of 62 patients, 24 weeks of treatment allowed roughly 75% reductions in the doses of calcium and active vitamin D supplements needed to maintain normal blood calcium. Blood markers of bone rebuilding increased, confirming the skeleton was responding to restored PTH signaling.
MedicationStrong Evidence
Decrease
Cholecalciferol (vitamin D3) supplementation
Correcting vitamin D deficiency removes a key driver of secondary PTH elevation. In a randomized trial of 193 vitamin D-deficient kidney transplant recipients, 4,000 IU/day of cholecalciferol for 11 months raised 25-hydroxyvitamin D from about 10 to 40 ng/mL and lowered whole PTH by approximately 15% compared to placebo. This PTH reduction accounted for about 39% of the benefit seen in lumbar spine bone density preservation.
SupplementModerate Evidence
Decrease
Combined vitamin D, calcium, protein supplementation, and structured exercise after bariatric surgery
Bariatric surgery tends to push PTH upward by impairing calcium and vitamin D absorption. A multifactorial intervention (28,000 IU vitamin D weekly preoperatively, then 16,000 IU weekly plus 1,000 mg calcium daily, protein supplementation, and structured exercise) reduced the magnitude of PTH rise over 24 months. Intact PTH fell by 17.3% in the intervention group versus 7.6% in controls, and increases in bone breakdown markers were markedly attenuated.
LifestyleModerate Evidence

Frequently Asked Questions

References

20 studies
  1. Silverberg S, Gao P, Brown I, Logerfo P, Cantor T, Bilezikian JThe Journal of Clinical Endocrinology and Metabolism2003
  2. Sprague S, Bellorín-font E, Jorgetti V, Carvalho a, Malluche H, Ferreira a, D'haese P, Drüeke T, Du H, Manley T, Rojas E, Moe SAmerican Journal of Kidney Diseases2016
  3. Inaba M, Okuno S, Imanishi Y, Ueda M, Yamakawa T, Ishimura E, Nishizawa YOsteoporosis International2005